Dopamine and Serotonin - Drug Design and Discovery - page 312

18.4 CONCLUDINGREMARKS
DA, 5-HT, and NE receptors and transporters have shown their relevance as drug targets, and
although research toward the pharmacotherapy of schizophrenia and depression nowadays are
targeting other targets as well, future antipsychotics and antidepressants may very well interact
with these receptors and sites also. Recently, it has been shown that DA signals via several different
second messenger systems and as discussed earlier an allosteric site has been identii ed on SERT.
Only the future will tell us whether these new discoveries will result in new and effective pharma-
cotherapies based on the DA and 5-HT systems.
FURTHER READINGS
Gether, U., Andersen, P. H., Larsson O. M., and Schousboe, A. (2006) Neurotransmitter transporters: Molecular
function of important drug targets. Trends Pharmacol. Sci ., 27 , 375-383.
Gray, J. A. and Roth, B. L. (2007) The pipeline and future of drug development in schizophrenia. Mol.
Psychiatry , 12 , 904-922.
Hyttel, J. (1994) Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int. Clin.
Psychopharmacol ., 9 (Suppl. 1), 19-26.
Jørgensen, A. M., Tagmose, L., Jørgensen, A. M. M., Topiol, S., Sabio, M., Gundertofte, K., Bøgesø, K. P.,
and Peters, G. H. (2007) Homology modeling of the serotonin transporter: Insight into the primary
escitalopram-binding site. ChemMedChem , 2 , 815-826.
Moltzen, E. K. and Bang-Andersen, B. (2006) Serotonin reuptake inhibitors: The corner stone in treatment of
depression for half a century—A medicinal chemistry survey. Curr. Top. Med. Chem ., 6 , 1801-1823.
Sánchez, C., Bøgesø, K. P., Ebert, B., Reines, E. H., and Bræstrup, C. (2004) Escitalopram versus citalopram:
The surprising role of the R -enantiomer. Psychopharmacology , 174 , 163-176.
Werkman, T. R., Glennon, J. C., Wadman, W. J., and McCreary, A. C. (2006) Dopamine receptor pharmacology:
Interactions with serotonin receptors and signii cance for the aetiology and treatment of schizophrenia.
CNS Neurol. Disord. Drug Targets , 5 , 3-23.
Wood, M. and Reavill, C. (2007) Aripiprazole acts as a selective dopamine D 2 receptor partial agonist. Expert
Opin. Invest. Drugs , 16 , 771-775.
Yamashita, A., Singh, S. K., Kawate, T., Jin, Y., and Gouaux, E. (2005) Crystal structure of a bacterial homologue
of Na + /Cl − -dependent neurotransmitter transporters. Nature , 437 , 215-223.